Please select the option that best describes you:
When, if ever, would you re-challenge with immunotherapy for patients with metastatic RCC?
How are you incorporating CONTACT-03 data presented at #ASCO2023 (Pal et al., PMID 37290461) into your practice? Would you consider immunotherapy re-challenge for someone on adjuvant pembrolizumab? What about for someone whose last immunotherapy exposure was >1 year ago?
Answer from: Medical Oncologist at Academic Institution
Checkpoint inhibitors combinations (IO/IO and TKI/IO) are the most likely way for a patient to experience a durable response. However, we need better treatment options for patients who are experiencing disease progression to these therapies. A number of new immune treatments are currently in clinica...
Sign in or Register to read more